hu14.18-IL2 fusion protein

BIOLOGICAL3 trials

Sponsors

Children's Oncology Group, University of Wisconsin, Madison

Conditions

Melanoma (Skin)NeuroblastomaRecurrent NeuroblastomaSarcomaUnspecified Childhood Solid Tumor, Protocol Specific

Phase 1

Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors

CompletedNCT00003750

Children's Oncology GroupMelanoma (Skin), Neuroblastoma, Sarcoma +1

Start: 2001-10-31End: 2005-09-30Updated: 2014-08-08

Phase 2

Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma

CompletedNCT00109863

University of Wisconsin, MadisonMelanoma (Skin)

Start: 2005-05-31End: 2014-02-28Updated: 2019-11-19

Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

CompletedNCT01334515

Children's Oncology GroupRecurrent Neuroblastoma

Start: 2011-09-30End: 2019-09-30Updated: 2019-10-21

Related Papers

A feasibility and phase II study of the hu14.18-IL2 immunocytokine in combination with GM-CSF and isotretinoin in patients with recurrent or refractory neuroblastoma: A Children’s Oncology Group study.

Journal of Clinical Oncology2015-05-2011 citations